Tianjin has had a good foundation for the development in respect of the R & D and industrialization of its biotechnology, biomedicine and modern Chinese medicine: for the first time in the world it has isolated, identified, and prepared a new human stem cell factor hemangiopoietin, developed a number of innovative drugs that have entered clinical study like anti-AIDS membrane fusion inhibitors, and bred the first cloned Boer goat, having obvious advantages in the fields of stem cells, biochips, bio-medicine, etc. Among the existing more than 100 biomedical companies in Tianjin, three rank among the top 10 Chinese pharmaceutical enterprises. This ratio has reached 42% in Binhai New Area. There have been more than 500 domestic enterprises and research institutions engaged in the production of biotechnology-related products, with the annual sale revenue of 30 billion yuan in their biotechnology industry, and a large number of technologies and products with independent intellectual property rights. In the Tianjin Economic - Technological Development Area (TEDA), a chain of biotechnology industry that integrates product R&D, technology transfer, manufacturing, commercial logistics and demonstration & intercourses has begun to take shape. TEDA is making every effort to create a biomedical industrialization base with international competitiveness.

I. Current Situation of the Industry

1. Industrial Convergence

There are 104 bio-pharmaceutical enterprises, 45 foreign-funded enterprises and 59 domestic-funded enterprises, forming a convergence characteristic with foreign-funded enterprises playing the major role in manufacturing and domestic-funded enterprises in scientific and technological innovation.

2. Industrial Scale

From 2001 to 2007, the annual rate of TEDA's biomedical output was 37%, which was higher than the national growth rate.

TEDA's Biomedical Output Growth

3. Industrial Orientation

CRO: Medicinal Chemistry, Active Filtration, Technics, Pharmacology, Safety Assessment, Clinical Medicine Pharmaceutical Equipment: Diagnostic Reagents, Testing Equipment, Interventional Treatment Chemical Drugs: Characterized Raw Material Medicine, Generic Drugs Biopharmaceuticals: Culture of Mammalian Cells (CMO), Monoclonal Antibody Herbal Medicine: Plant Extraction, Compound Preparations

Focused Areas: CRO Areas: Compound Screening, Pharmacology, Pharmacodynamics, Pharmacokinetics, Drug Toxicity, Animal Testing, Study of Drug Forms, etc. Medical Devices: Diagnostic Reagents, Test Instrument, Interventional Therapy, Bone Equipment and others. CMO Areas: Contract Manufacturing for High Value-added API and Generic Drugs, Large-scale Mammalian-Cell-Culture-Based Bio-pharmaceutical Production Base.

4. Leading Enterprises

5. TEDA's Industry-Leading Biomedical Enterprises

6. Leading Products

7. Investment in R & D

TEDA has an accumulated investment of more than 200 million yuan to support the construction of its innovation system of biomedical industry. At present, it has 4 national-level R & D centers, 5 enterprise technology centers, 12 enterprise engineering centers, and 167 accumulated biomedicine patents.

II. Advantages of TEDA

Location and Market Advantages: TEDA is located in the heart of the Bohai Sea Economic Circle, adjacent to the port, close to the two major municipalities of Tianjin and Beijing. It has a population of more than 20 million, and its pharmaceutical sales accounts for one fifth of the nation.
	Talent Advantages: There are 200 tertiary institutions within the 150-km city circle of Beijing-Tianjin. Every year, there are more than 5000 graduates majored in chemistry, biology, medicine and other related majors, nearly 200,000 personnel engaged in related scientific researches, and more than 2 million industrial workers.
R & D Advantages: Tianjin has such a number of research institutions as Tianjin Industrial Biotechnology R & D Center, Chinese Academy of Sciences (TIBC, CAS), and Tianjin Institute of Pharmaceutical Research (TIPR). In the Tenth Five-Year Period, it obtained a total of more than 300 certificates for various types of new drugs. Beijing has 31.9% national laboratories of key disciplines in medical category, and state key laboratories of life sciences which account for 41% of the country.
	Clinical Advantages: Tianjin and Beijing have 60 A-level hospitals, and a number of clinical bases confirmed by the State Food and Drug Administration (SFDA), involving many fields like cardiovascular diseases, blood, tumor, surgery, geriatrics, infectious diseases.

Policy Advantages: Set up the "Special Fund for TEDA's Biomedical Industry", with an annual budget of 200 million yuan, providing a full range of support in land, workshop, equipment, funds, taxes, personnel and others. As a "special economic area" of the Central Government, TEDA is a pilot in reform for the simplified approval procedures of medication, customs inspection and quarantine for testing samples, and exemption of imported equipment.

Advantages of Government Services: It provides professional services, including: expert advice, public facilities, financing, academic exchanges, patent agency, vocational training and so on. It set up an expert advisory committee, invested nearly 70 million yuan in public equipment, and established Regional Equipment-Sharing Networks, Bole (China) Life Science Venture Capital Funds and other 3 financial institutions.

[1]

[2]

[3]